Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
Emphysema
About this trial
This is an interventional basic science trial for Emphysema
Eligibility Criteria
Inclusion Criteria:
- Must be between the ages of 25 and 65.
- Must be currently smoking at least 1/2 pack/day (confirmed with cotinine level).
Must have pulmonary function test (PFT) results that meet the following (there will be two groups):
Group 1:
- Forced expiratory volume at one second (FEV1)/Forced vital capacity (FVC) > 70%
- Forced Expiratory Flow at 25-75% of predicted(FEF25-75) > 79% of predicted
- FVC greater than 80% of predicted
Group 2:
For subjects with mild lung impairment:
- FEV1>80% of predicted
- FEV1/FVC<0.7
- Must be able to give informed consent for self.
Exclusion Criteria:
- Pregnant or breastfeeding females.
- Body Mass Index (BMI) greater than 32.
- Weight of greater than 220 pounds (100 kg).
- Allergies to shell fish, seafood, eggs or iodine.
- Heart disease, kidney disease or diabetes.
- Diagnosis of asthma.
- Usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics EXCEPT aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed).
- Any metal in or on the body between the nose and the abdomen.
- Any major organ system disease (by judgment of study medical team).
- A glomerular filtration rate of 60 cc per minute or less.
For the subjects that will receive Sildenafil as part of the study, additional exclusion criteria are as follows:
- Nitroglycerin usage or nitrates (in addition to nitroglycerin) and use of phosphodiesterase 5 (PDE5) inhibitors within the previous 7 days of the study date.
- Prior history of hypersensitivity to Sildenafil.
Sites / Locations
- University of IowaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Hypoxia Administration study group
Hyperoxia Administration study group
Sildenafil
40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.